Literature DB >> 12044989

Altered cannabinoid receptor mRNA expression in peripheral blood mononuclear cells from marijuana smokers.

Liang Nong1, Catherine Newton, Qingwen Cheng, Herman Friedman, Michael D Roth, Thomas W Klein.   

Abstract

We studied, using RT-PCR, the relative expression of cannabinoid receptor (CBR) mRNA in peripheral blood mononuclear cells (PBMC) from different donor groups. Cells from normal donors expressed a CB2 mRNA level threefold higher than CB1 across all age, gender or ethnicity groups, and amplicons were of the same size in all donors. However, cells from marijuana users expressed higher levels of CBR mRNA, but with a preserved CB1/CB2 ratio of 1:3. CBR gene products were also studied following short-term mitogen activation in vitro. CB1 expression decreased following mitogen stimulation when compared to the time-matched medium only cells while the expression of CB2 mRNA remained unchanged. These studies suggest that marijuana smoking and immune activation can alter the basal levels of CB1 and CB2 in PBMCs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12044989     DOI: 10.1016/s0165-5728(02)00113-3

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  17 in total

1.  Increased CB2 mRNA and anandamide in human blood after cessation of cannabis abuse.

Authors:  Daniela Muhl; Markus Kathmann; Carolin Hoyer; Laura Kranaster; Martin Hellmich; Christoph W Gerth; Johannes Faulhaber; Eberhard Schlicker; F Markus Leweke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-05-02       Impact factor: 3.000

2.  Cannabinoid influence on cytokine profile in multiple sclerosis.

Authors:  S Katona; E Kaminski; H Sanders; J Zajicek
Journal:  Clin Exp Immunol       Date:  2005-06       Impact factor: 4.330

3.  Peripheral endocannabinoid system dysregulation in first-episode psychosis.

Authors:  Miquel Bioque; Borja García-Bueno; Karina S Macdowell; Ana Meseguer; Pilar A Saiz; Mara Parellada; Ana Gonzalez-Pinto; Roberto Rodriguez-Jimenez; Antonio Lobo; Juan C Leza; Miguel Bernardo
Journal:  Neuropsychopharmacology       Date:  2013-07-04       Impact factor: 7.853

4.  Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters.

Authors:  Michelle Sexton; Eiron Cudaback; Rehab A Abdullah; John Finnell; Laurie K Mischley; Mary Rozga; Aron H Lichtman; Nephi Stella
Journal:  Inflammopharmacology       Date:  2014-08-19       Impact factor: 4.473

5.  Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders.

Authors:  Dario Siniscalco; Anna Sapone; Catia Giordano; Alessandra Cirillo; Laura de Magistris; Francesco Rossi; Alessio Fasano; James Jeffrey Bradstreet; Sabatino Maione; Nicola Antonucci
Journal:  J Autism Dev Disord       Date:  2013-11

6.  Heavy marijuana users show increased serum apolipoprotein C-III levels: evidence from proteomic analyses.

Authors:  S Jayanthi; S Buie; S Moore; R I Herning; W Better; N M Wilson; C Contoreggi; J L Cadet
Journal:  Mol Psychiatry       Date:  2008-05-13       Impact factor: 15.992

7.  Regulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by interferon-β: a longitudinal study in multiple sclerosis patients.

Authors:  A J Sánchez López; L Román-Vega; E Ramil Tojeiro; A Giuffrida; A García-Merino
Journal:  Clin Exp Immunol       Date:  2015-01       Impact factor: 4.330

8.  Characterization of anandamide-stimulated cannabinoid receptor signaling in human ULTR myometrial smooth muscle cells.

Authors:  Paul J Brighton; John McDonald; Anthony H Taylor; R A John Challiss; David G Lambert; Justin C Konje; Jonathon M Willets
Journal:  Mol Endocrinol       Date:  2009-05-28

9.  Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells.

Authors:  E Gkoumassi; B G J Dekkers; M J Dröge; C R S Elzinga; M Schmidt; H Meurs; J Zaagsma; S A Nelemans
Journal:  Br J Pharmacol       Date:  2007-06-11       Impact factor: 8.739

10.  Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors.

Authors:  Maria Teresa Cencioni; Valerio Chiurchiù; Giuseppina Catanzaro; Giovanna Borsellino; Giorgio Bernardi; Luca Battistini; Mauro Maccarrone
Journal:  PLoS One       Date:  2010-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.